CTLA4 and melanoma: This was based on their previous studies, showing that the methylation status of the CTLA4 gene predicts response to both anti-PD-1 and anti-CTLA-4 targeted ICB as well as anti-CTLA-4 monotherapy in patients with melanoma [66,67].